← Tra cứu cổ phiếu
Viewing Quý 1/2026Latest period →

iShareInvest Research

UPCOM · Quý 1/2026

MKP

Hoá - Dược phẩm Mekophar

Analysis of business results & financial statements · Quý 1/2026

▲▲ Improving positively

Trailing net profit reached 29.1bn, rose 13.4bn compared with the same period last year. Key positives came from higher gross profit and lower selling expenses. Offsetting pressure came mainly from lower financial income. Detailed impact is shown below:

See what is changing ↓
P/E
22.20x
P/B
0.50x
EPS
1,131
BVPS
49,758
ROE
2.3%
ROA
1.8%
Market price
25,100
13 Oct 2026

What Is Changing

On a TTM 2026Q1 basis, MKP is improving on both growth and profitability, painting a notably more positive picture versus the same period — profit is at an all-time high. However, a significant portion of profit is supported by non-core sources, making the picture not entirely clear.

Profit bridge

Vs last year · TTM

  1. Gross profit
  2. Selling expenses
  3. Financial income
Unit: VND bn. Green bars support profit; red bars reduce profit.

A single data point, or a trajectory?

Latest eight quarters · Quý 1/2026

MetricQ1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24
Revenue207.9342.8226.3197.5229.7244.8204.9224.6
LNST1.653.1-9.7-15.9-13.528.96.5-6.2
Net margin0.78%15.48%-4.28%-8.04%-5.86%11.80%3.18%-2.78%

Revenue

208bn

Net income

2bn

Net margin

0.78%

A closer look at what is happening inside the business

A company's statements are read with the questions that fit its type of business.

01

Is the profit sustainable?

Margins improved (+1.3pp), but earnings still rely significantly on non-core sources — warrants closer scrutiny.

What is driving the margin?

▲

Net margin edged up to 2.99%, rising 1.3pp. The main driver is Gross margin rose 4.8pp and SG&A / Revenue fell 2.4pp, moving in line with the stronger net margin (in addition, Other profit / Revenue rose 0.1pp added support while Net financial result / Revenue fell 5.8pp remained a drag).

Margin improves from both core operations and non-core items — the core foundation is positive, but the sustainability of non-core contributions needs monitoring.

Net Margin
2.99%
+1.3pp
Gross Margin
29.47%
+4.8pp
SG&A / Revenue
26.63%
−2.4pp
Non-core / Revenue
1.39%
−5.7pp

TTM YoY · 2025Q1 -> 2026Q1

Financial result share remains high

Even though contribution decreased by 5.7pp, financial result still accounts for 32.8% of PBT — earnings durability should be monitored in coming periods.

02

Is capital being used efficiently?

Evaluate capital, asset, and working-capital efficiency.

Balance Sheet

▲

Balance sheet is exceptionally sound — liabilities at 0.31x equity, with a net cash position equivalent to 0.16x equity.

Inventory ended the period at 640.5bn, roughly 38.6% of total assets.

Over the last 12 months, working capital released 122.6bn of cash, mainly thanks to lower inventories and higher payables. Pressure from higher receivables only partly offset that benefit.

Working Capital Efficiency

▲

Working capital is being managed more efficiently, supporting overall capital efficiency. Cash conversion cycle improved by 3.7 days versus the same period last year. The main moves came from DIO rose 3.9 days, DSO fell 0.7 days, and DPO rose 6.9 days.

Extended payment timing is the main driver — consider whether this trades off supplier relationships.

Cash conversion cycle remains stretched

CCC stands at 345.1 days, suggesting that working capital remains tied up for a relatively long operating cycle.

Inventory turnover is slowing

DIO increased by +3.9 days, suggesting more capital is being tied up in inventories.

DuPont

What drives ROE?

Net margin 3.0% +1.3pp
Asset turnover 0.59x +0.03x
Financial leverage 1.29x +0.03x
ROE 2.3% +1.1pp

ROE rose from 1.2% to 2.3% — all three components improved, with net margin contributing the most.

03

Is financial risk significant?

Financial risk is low — the company has net cash and CFO reached 64.8bn.

Leverage & Liquidity

▲

Leverage looks fairly comfortable, with net debt / equity at −0.16x and interest coverage at 16.01x.

Debt maturity and the cash buffer remain the two key areas to monitor.

Some leverage signals are missing, so the current read should be treated as contextual.

Net Debt / Equity
−0.16x
Interest Coverage
16.01x
+8.64x
Cash / Debt
None
Short-term Debt / Total Debt
None

TTM YoY · 2025Q1 -> 2026Q1

Cash Flow

▲▲

With safe leverage noted above, cash flow below shows the self-funding capacity. Operating cash flow reached 64.8bn in 2025, against investing cash flow of 28.0bn.

Post-investment cash flow was positive +92.8bn. Financing cash flow was negative +12.6bn.

CFO / net income was 4,80 lần.

After spending +18.5bn on fixed-asset investment, the business generated trailing free cash flow of +121.3bn.

Research synthesis

What this reporting period is showing

The business is heading the right way, but the current picture is still at partial confirmation — not yet a fully clean case. The positive points have clearly improved, showing the operating base is better than before. The brighter spot is operating efficiency, with net margin improving 1.3 pp. Even so, earnings quality still needs closer monitoring because net financial result remains elevated. The main risk still sits in working capital is tied up too long in the operating cycle, with CCC extended to 345 days.

  • Improvement: operating efficiency is getting better, with trailing-12M net margin at 2.99% after expanding 1.3pp versus the same period last year.
  • Watchpoint: cash flow is currently keeping pace with accounting earnings, with CFO / net income at 4.80x. Even so, net financial result still accounts for 30.3% of PBT, so the earnings mix still needs monitoring.
  • Key risk: working capital remains tied up for too long, with cash cycle at 345.1 days.

Questions for the next period

  1. Durability of revenue growth after the current +7,8% YoY pace.

  2. Ability to hold margins around the current 2.99% level.

  3. Cash-flow quality, with operating cash flow currently at 64.8bn in 2025.

From one stock to the whole portfolio

Where does this stock stand
among the rest of your investments?

Each stock is only one part of the wider picture. Looking at investments side by side makes their contribution, risks and opportunities across the portfolio clearer.

How much does this stock
contribute to the portfolio?

Its weight and influence across the assets held for investment.

Is the portfolio
well balanced?

How holdings, sectors and asset groups are distributed in relation to overall risk.

What other opportunities
or risks may be present?

What becomes visible only when investments are viewed together rather than one ticker at a time.

View my portfolio